Toll Free: 1-888-928-9744

Immupharma Plc - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 33 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Immupharma Plc - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Immupharma Plc - Product Pipeline Review - 2014', provides an overview of the Immupharma Plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Immupharma Plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Immupharma Plc including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Immupharma Plc's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Immupharma Plc's pipeline products

Reasons to buy

- Evaluate Immupharma Plc's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Immupharma Plc in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Immupharma Plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Immupharma Plc and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Immupharma Plc
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Immupharma Plc and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Immupharma Plc Snapshot 5
Immupharma Plc Overview 5
Key Information 5
Key Facts 5
Immupharma Plc - Research and Development Overview 6
Key Therapeutic Areas 6
Immupharma Plc - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Immupharma Plc - Pipeline Products Glance 10
Immupharma Plc - Late Stage Pipeline Products 10
Phase III Products/Combination Treatment Modalities 10
Immupharma Plc - Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
Immupharma Plc - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
Immupharma Plc - Drug Profiles 14
forigerimod 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
IPP-204106 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
IPP-102199 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
IPP-203101 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
IPP-201007 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Small Molecule for Undisclosed Indication 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Immupharma Plc - Pipeline Analysis 22
Immupharma Plc - Pipeline Products by Target 22
Immupharma Plc - Pipeline Products by Route of Administration 23
Immupharma Plc - Pipeline Products by Molecule Type 24
Immupharma Plc - Pipeline Products by Mechanism of Action 25
Immupharma Plc - Recent Pipeline Updates 26
Immupharma Plc - Discontinued Pipeline Products 28
Discontinued Pipeline Product Profiles 28
forigerimod 28
Immupharma Plc - Company Statement 29
Immupharma Plc - Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33
List of Tables
Immupharma Plc, Key Information 5
Immupharma Plc, Key Facts 5
Immupharma Plc - Pipeline by Indication, 2014 7
Immupharma Plc - Pipeline by Stage of Development, 2014 8
Immupharma Plc - Monotherapy Products in Pipeline, 2014 9
Immupharma Plc - Phase III, 2014 10
Immupharma Plc - Phase I, 2014 11
Immupharma Plc - Preclinical, 2014 12
Immupharma Plc - Discovery, 2014 13
Immupharma Plc - Pipeline by Target, 2014 22
Immupharma Plc - Pipeline by Route of Administration, 2014 23
Immupharma Plc - Pipeline by Molecule Type, 2014 24
Immupharma Plc - Pipeline Products by Mechanism of Action, 2014 25
Immupharma Plc - Recent Pipeline Updates, 2014 26
Immupharma Plc - Discontinued Pipeline Products, 2014 28
Immupharma Plc, Subsidiaries 31 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify